AI model to predict how pyrotinib works for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study uses artificial intelligence to look at your tumor samples and predict how well pyrotinib (a targeted pill) will work for your advanced breast cancer. It may help guide future treatment decisions by finding patterns that predict response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have advanced (stage IV) breast cancer confirmed by biopsy.
- Your tumor's HER2 status is known (this helps doctors choose targeted therapy).
- You have already received at least 2 cycles of pyrotinib (a targeted therapy pill) or you plan to start it as a second or later line of treatment.
- You have stored tumor tissue slides (from biopsy or surgery) that can be reviewed by the study team.
- You have not been treated with another HER2 antibody-drug conjugate (like T-DM1 or DS-8201) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an artificial intelligence model can help doctors choose the best targeted therapy before surgery for HER2-positive breast cancer (a type of breast cancer with a protein called HER2). The goal is to improve how well the treatment works and reduce side effects.
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
This study looks at how well the drug pyrotinib works in people with advanced breast cancer that has spread and tests positive for HER2. HER2 is a protein that can make cancer cells grow, and pyrotinib targets it. If you have this type of breast cancer, this study may show if the treatment helps you.
This trial uses an artificial intelligence model to predict how well breast cancer responds to neoadjuvant therapy (treatment before surgery). It aims to improve treatment planning by analyzing MRI scans taken before and after therapy.
This study tests giving certain targeted drugs before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach helps reduce tumor size and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.